What Researchers Did
Researchers conducted a review to summarize current knowledge on angiogenesis, antiangiogenic therapies, and their potential combination with radiotherapy.
What They Found
They found that angiogenesis is a crucial process for tumour growth and metastasis, regulated by multiple factors. Antiangiogenic therapies have demonstrated positive results in clinical trials, are approved as standard of care in medical oncology, and are being evaluated in numerous trials in combination with radiotherapy.
What This Means for Canadian Patients
Canadian patients may benefit from antiangiogenic therapies, which are already part of standard cancer care, particularly as research continues to explore their effectiveness when combined with radiation. Understanding the role of angiogenesis helps inform treatment strategies that aim to starve tumours of their blood supply, potentially improving outcomes for various cancers.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a review article published in 2008, this study synthesizes existing knowledge and may not reflect the most recent advancements in antiangiogenic therapies and their combination with radiotherapy.